Vinorelbine, Cisplatin, Disulfiram and Copper in CTC_EMT Positive Refractory Metastatic Breast Cancer.
Status:
Recruiting
Trial end date:
2023-01-01
Target enrollment:
Participant gender:
Summary
This is a proof-of-concept study to define efficacy of vinorelbine, cisplatin, disulfiram and
copper in CTC_EMT positive refractory metastatic hormone receptor positive, HER2 negative
breast cancer.